HER2 aberrations in cancer: implications for therapy.

[1]  S. Lippman,et al.  Human epidermal receptor 2–amplified salivary duct carcinoma: Regression with dual human epidermal receptor 2 inhibition and anti–vascular endothelial growth factor combination treatment , 2014, Head & neck.

[2]  M. Hidalgo,et al.  Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Sliwkowski,et al.  Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy , 2013, Clinical Cancer Research.

[5]  W. Sellers,et al.  An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. , 2013, Cancer research.

[6]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Pearson,et al.  Clinical and molecular characterization of HER2 amplified-pancreatic cancer , 2013, Genome Medicine.

[8]  P. Hui,et al.  Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice , 2013, Modern Pathology.

[9]  S. Peters,et al.  Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  X. Bian,et al.  Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. , 2013, World journal of gastroenterology.

[11]  N. Boku.  HER2-positive gastric cancer , 2013, Gastric Cancer.

[12]  R. Kurzrock,et al.  A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R): Implications for Inhibition of the IGF-1R signal , 2013, Oncotarget.

[13]  A. Tsao,et al.  Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  Li Ding,et al.  Activating HER2 mutations in HER2 gene amplification negative breast cancer. , 2013, Cancer discovery.

[15]  A. Tinker,et al.  Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas , 2013, The Journal of pathology.

[16]  P. Kuppen,et al.  Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer , 2013, Clinical Medicine Insights. Oncology.

[17]  L. Bosserman,et al.  Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen , 2012, Breast Cancer Research and Treatment.

[18]  N. Andreollo,et al.  Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas , 2012, BMC Cancer.

[19]  Julie M. Batten,et al.  Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment , 2012, Clinical Cancer Research.

[20]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[21]  M. Ranson,et al.  A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer. , 2012, Clinical lung cancer.

[22]  C. Klein,et al.  Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker , 2012, Journal of Pharmacology and Experimental Therapeutics.

[23]  L. Law.  Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Giaccone,et al.  HER2 mutations in non-small-cell lung cancer can be continually targeted. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Liu,et al.  HER2 expression in renal cell carcinoma is rare and negatively correlated with that in normal renal tissue. , 2012, Oncology letters.

[26]  W. Lewis,et al.  Systematic Review and Meta-analysis of the Influence of HER2 Expression and Amplification in Operable Oesophageal Cancer , 2012, Journal of Gastrointestinal Surgery.

[27]  J. Baselga,et al.  Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Ladanyi,et al.  Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas , 2012, Clinical Cancer Research.

[29]  J. Fregnani,et al.  Prognostication of Soft Tissue Sarcomas Based on Chromosome 17q Gene and Protein Status: Evaluation of TOP2A, HER-2/neu, and Survivin , 2012, Annals of Surgical Oncology.

[30]  A. Stojadinovic,et al.  Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patients , 2012, Cancer.

[31]  I. Umelo,et al.  Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. , 2012, Lung cancer.

[32]  A. Lluch,et al.  Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. , 2012, The oncologist.

[33]  M. Galsky,et al.  Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors , 2012, Investigational New Drugs.

[34]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[35]  C. Schmoor,et al.  Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer , 2012, British Journal of Cancer.

[36]  S. Kane,et al.  A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer , 2012, Breast Cancer Research and Treatment.

[37]  Tsung-Teh Wu,et al.  Association of HER2/ErbB2 Expression and Gene Amplification with Pathologic Features and Prognosis in Esophageal Adenocarcinomas , 2012, Clinical Cancer Research.

[38]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[39]  M. Brechbiel,et al.  212Pb-Radioimmunotherapy Induces G2 Cell-Cycle Arrest and Delays DNA Damage Repair in Tumor Xenografts in a Model for Disseminated Intraperitoneal Disease , 2012, Molecular Cancer Therapeutics.

[40]  C. Hudis,et al.  A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer , 2011, Breast Cancer Research and Treatment.

[41]  S. Gottschalk,et al.  Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma , 2011, Cancer Gene Therapy.

[42]  P. Moore,et al.  Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties , 2011, Breast Cancer Research.

[43]  Davide Corà,et al.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.

[44]  Y. Yatabe,et al.  Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. , 2011, Lung cancer.

[45]  E. Winer,et al.  Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  U. Studer,et al.  Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. , 2011, European urology.

[47]  W. McCluggage,et al.  Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. , 2011, Pathology.

[48]  P Sebastian,et al.  Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck , 2011, British Journal of Cancer.

[49]  Daorong Wang,et al.  Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas , 2011, BMC Cancer.

[50]  M. Rosemann,et al.  Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma. , 2011, Human pathology.

[51]  C. Ching,et al.  HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization , 2011, Modern Pathology.

[52]  A. Ashworth,et al.  Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas , 2011, Clinical Cancer Research.

[53]  Y. Tyan,et al.  Identification of the Coexisting HER2 Gene Amplification and Novel Mutations in the HER2 Protein-Overexpressed Mucinous Epithelial Ovarian Cancer , 2011, Annals of Surgical Oncology.

[54]  N. Funel,et al.  Mutational Profiling of Kinases in Human Tumours of Pancreatic Origin Identifies Candidate Cancer Genes in Ductal and Ampulla of Vater Carcinomas , 2010, PloS one.

[55]  D. Niedzwiecki,et al.  An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. , 2010, The Journal of clinical investigation.

[56]  M. Wroclawski,et al.  Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. , 2010, The Journal of urology.

[57]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[58]  Xiong Cai,et al.  CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. , 2010, Cancer research.

[59]  R. Weber,et al.  Genetic and Expression Analysis of HER-2 and EGFR Genes in Salivary Duct Carcinoma: Empirical and Therapeutic Significance , 2010, Clinical Cancer Research.

[60]  K. Gelmon,et al.  Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  M. Sliwkowski,et al.  Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Hartwig Huland,et al.  Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer , 2010, Clinical Cancer Research.

[63]  Anna Adamiak,et al.  HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy , 2009, BMC Cancer.

[64]  F. Radvanyi,et al.  Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  S. Hamilton-Dutoit,et al.  HER2/neu (c‐erbB‐2) gene amplification and protein expression are rare in uterine cervical neoplasia: a tissue microarray study of 814 archival specimens , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[66]  K. Wakasa,et al.  HER2 overexpression correlates with survival after curative resection of pancreatic cancer , 2009, Cancer science.

[67]  M. Birrer,et al.  Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. , 2009, Gynecologic oncology.

[68]  L. Bosserman,et al.  A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. , 2009, Clinical breast cancer.

[69]  J. de-la-Cruz,et al.  Negative Prognostic Impact of the Coexpression of Epidermal Growth Factor Receptor and c-erbB-2 in Locally Advanced Cervical Cancer , 2009, Oncology.

[70]  D. Kavanagh,et al.  Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? , 2009, BMC Cancer.

[71]  John M Lambert,et al.  Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.

[72]  M. Olschewski,et al.  EGFR and HER2 expression in advanced biliary tract cancer. , 2008, World journal of gastroenterology.

[73]  T. Henkel,et al.  Assessment of a HER2 scoring system for gastric cancer: results from a validation study , 2008, Histopathology.

[74]  S. Hirohashi,et al.  Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma , 2007, British Journal of Cancer.

[75]  M. Meyerson,et al.  PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. , 2007, Cancer research.

[76]  Philippe Broët,et al.  HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients , 2007, PloS one.

[77]  J. Sercarz,et al.  Salivary duct carcinoma: A clinical and histologic review with implications for trastuzumab therapy , 2007, Head & neck.

[78]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[79]  Philippe Dessen,et al.  A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. , 2007, Cancer research.

[80]  C. Maurage,et al.  Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma , 2007, Journal of Neuro-Oncology.

[81]  P. Jänne,et al.  Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  Robert D. Cardiff,et al.  Insights from transgenic mouse models of ERBB2-induced breast cancer , 2007, Nature Reviews Cancer.

[83]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[84]  C. Plass,et al.  A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma , 2006, BMC Cancer.

[85]  F. Cappuzzo,et al.  HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. , 2006, The New England journal of medicine.

[86]  C. Morrison,et al.  HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  W. Scheithauer,et al.  HER 2/neu protein expression in colorectal cancer , 2006, BMC Cancer.

[88]  A. Dueñas-González,et al.  Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. , 2006, Cancer treatment reviews.

[89]  Jorma Isola,et al.  Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma , 2006, Journal of Molecular Medicine.

[90]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[91]  W. Park,et al.  Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas , 2006, Clinical Cancer Research.

[92]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[93]  W. Cong,et al.  Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma , 2005, Journal of Clinical Pathology.

[94]  J. Minna,et al.  Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.

[95]  J. Izbicki,et al.  Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[97]  A. Dueñas-González,et al.  HER2 expression in cervical cancer as a potential therapeutic target , 2004, BMC Cancer.

[98]  O. Csuka,et al.  Clinical relevance of HER-2/neu expression in germ-cell testicular tumors. , 2004, Anticancer research.

[99]  S. Ariyan,et al.  Her2/neu is not a commonly expressed therapeutic target in melanoma – a large cohort tissue microarray study , 2004, Melanoma research.

[100]  Ramaswamy Nilakantan,et al.  Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase , 2004, Cancer Research.

[101]  M. Owens,et al.  HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. , 2004, Clinical breast cancer.

[102]  M. Sliwkowski,et al.  Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.

[103]  M. Vangel,et al.  Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  F. Hirsch,et al.  The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. , 2004, Seminars in oncology.

[105]  R. Day,et al.  Low Overexpression of HER-2/Neu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (Herceptin®) and Irinotecan as Therapy. A Phase II Trial , 2004, Cancer investigation.

[106]  J. Rüschoff,et al.  HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[107]  E. Levine,et al.  Absence of HER2 overexpression in metastatic malignant melanoma , 2003, Journal of surgical oncology.

[108]  J. Verdebout,et al.  The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature , 2003, British Journal of Cancer.

[109]  A. Potti,et al.  Role of Her-2/neu Overexpression and Clinical Determinants of Early Mortality in Glioblastoma Multiforme , 2003, American journal of clinical oncology.

[110]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[111]  P. Nuciforo,et al.  Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. , 2003, Human pathology.

[112]  Michael Kofler,et al.  The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.

[113]  K. Darcy,et al.  Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  Hong Ma,et al.  Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways , 2002, Oncogene.

[115]  K. Miller,et al.  HER-2/neu expression in germ cell tumours , 2002, Journal of clinical pathology.

[116]  M. Bissell,et al.  ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini , 2001, Nature Cell Biology.

[117]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[118]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[119]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[120]  M. Kraus,et al.  Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.

[121]  K. Olsen,et al.  Primary parotid malignancies. A clinical and pathologic review. , 1991, Archives of otolaryngology--head & neck surgery.

[122]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[123]  A. Ullrich,et al.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[124]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[125]  Ji-hoon Kim,et al.  Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection , 2013, Gastric Cancer.

[126]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[127]  K. Ghafarzadegan,et al.  Clinical relevance of HER-2/neu overexpression in patients with testicular nonseminomatous germ cell tumor. , 2010, Urology journal.

[128]  O. Olopade,et al.  An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[129]  F. Shepherd,et al.  Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[130]  L. Plank,et al.  Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. , 2001, Pathology, research and practice.